OCS

Oculis Holding AG

11.83 USD
-0.05 (-0.42%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Oculis Holding AG stock is down -1.25% since 30 days ago. The next earnings date is Aug 18, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Oculis Holding AG

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

  • Chardan Capital
    Tue Jun 11, 10:31
    buy
    confirm
  • Bank of America
    Tue Jun 11, 07:18
    buy
    confirm
  • HC Wainwright & Co.
    Tue Jun 11, 07:00
    buy
    confirm
  • Baird
    Tue Jun 11, 06:45
    buy
    confirm
  • HC Wainwright & Co.
    Thu May 30, 06:25
    buy
    confirm